Briefing on the Fundamentals of Teva Pharmaceutical Industries

By Emilio Sanchez • Wednesday, December 20 11:48 • Permanent Link

Teva Pharmaceutical Industries, a large-cap Pharmaceutical stock, moved -0.2% this morning. Here are some facts about the company that we're keeping an eye on:

Teva Pharmaceutical Industries has logged a 19.8% 52 week change, compared to 22.9% for the S&P 500
TEVA has an average analyst rating of hold and is -2.71% away from its mean target price of $10.9 per share
Its trailing earnings per share (EPS) is $-1.98, which brings its trailing Price to Earnings (P/E) ratio to -5.4. The Health Care sector's average P/E ratio is 30.21
The company's forward earnings per share (EPS) is $2.41 and its forward P/E ratio is 4.4
The company has a Price to Book (P/B) ratio of 1.72 in contrast to the Health Care sector's average P/B ratio is 4.08
TEVA has reported YOY quarterly earnings growth of 40.0% and gross profit margins of 0.5%
The company's free cash flow for the last fiscal year was $508.0 Million and the average free cash flow growth rate is 3.2%
Teva Pharmaceutical Industries's revenues have an average growth rate of -3.0% with operating expenses growing at -2.4%. The company's current operating margins stand at -7.5%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.